AR105401A1 - Mezcla acuosa que comprende un vector adenoviral, composición liofilizada, procedimiento - Google Patents
Mezcla acuosa que comprende un vector adenoviral, composición liofilizada, procedimientoInfo
- Publication number
- AR105401A1 AR105401A1 ARP160102193A ARP160102193A AR105401A1 AR 105401 A1 AR105401 A1 AR 105401A1 AR P160102193 A ARP160102193 A AR P160102193A AR P160102193 A ARP160102193 A AR P160102193A AR 105401 A1 AR105401 A1 AR 105401A1
- Authority
- AR
- Argentina
- Prior art keywords
- adenoviral vector
- liofilized
- mixting
- waterproof
- procedure
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 108700019146 Transgenes Proteins 0.000 abstract 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 229920002307 Dextran Polymers 0.000 abstract 1
- 241000282575 Gorilla Species 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 241000282576 Pan paniscus Species 0.000 abstract 1
- 241000282577 Pan troglodytes Species 0.000 abstract 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 239000002577 cryoprotective agent Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Una mezcla acuosa que comprende un vector adenoviral, un crioprotector que es un azúcar amorfo seleccionado de trehalosa, sacarosa, lactosa, rafinosa, dextrano, manitol y combinaciones de los mismos, y cloruro de sodio en una cantidad entre cero y 50 mM. Reivindicación 11: Una mezcla de acuerdo con cualquiera de las reivindicaciones anteriores, en la que el vector adenoviral es un vector adenoviral de simio no humano, tal como un vector adenoviral de chimpancé, un vector adenoviral de bonobo o un vector adenoviral de gorila. Reivindicación 30: Una mezcla de acuerdo con cualquiera de las reivindicaciones anteriores, en la que el vector adenoviral comprende un transgén que es un transgén inmunogénico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1513010.7A GB201513010D0 (en) | 2015-07-23 | 2015-07-23 | Novel formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105401A1 true AR105401A1 (es) | 2017-09-27 |
Family
ID=54106515
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102193A AR105401A1 (es) | 2015-07-23 | 2016-07-20 | Mezcla acuosa que comprende un vector adenoviral, composición liofilizada, procedimiento |
| ARP210100121A AR121079A2 (es) | 2015-07-23 | 2021-01-20 | Formulación |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100121A AR121079A2 (es) | 2015-07-23 | 2021-01-20 | Formulación |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10722470B2 (es) |
| EP (1) | EP3325016B1 (es) |
| JP (1) | JP6797891B2 (es) |
| CN (1) | CN108025081B (es) |
| AR (2) | AR105401A1 (es) |
| BE (1) | BE1023537B1 (es) |
| BR (1) | BR112018001260A2 (es) |
| CA (1) | CA2992922A1 (es) |
| GB (1) | GB201513010D0 (es) |
| MX (1) | MX391216B (es) |
| WO (1) | WO2017013169A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11047534B2 (en) | 2016-01-28 | 2021-06-29 | EcoSense Lighting, Inc. | Multizone mixing cup illumination system |
| KR20200066349A (ko) * | 2017-10-16 | 2020-06-09 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 복제 가능 아데노바이러스 벡터 |
| EP3720500A4 (en) * | 2017-12-05 | 2021-08-25 | Applied Genetic Technologies Corporation | FORMULATION OPTIMIZATION FOR VIRAL PARTICLES |
| GB201721069D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
| WO2019202083A1 (en) * | 2018-04-20 | 2019-10-24 | Laboratorio Reig Jofré, S.A. | Stable adenovirus compositions |
| EP3587581A1 (en) * | 2018-06-26 | 2020-01-01 | GlaxoSmithKline Biologicals S.A. | Formulations for simian adenoviral vectors having enhanced storage stability |
| CN109055432B (zh) * | 2018-08-16 | 2020-10-13 | 南京科佰生物科技有限公司 | 慢病毒感染试剂及其制备方法与应用 |
| CN120775062A (zh) | 2019-07-16 | 2025-10-14 | 吉利德科学公司 | Hiv疫苗及其制备和使用方法 |
| SI4037708T1 (sl) | 2019-09-30 | 2025-01-31 | Gilead Sciences, Inc. | Cepiva proti hbv in postopki zdravljenja hbv |
| KR20220129088A (ko) | 2020-02-04 | 2022-09-22 | 리제너론 파아마슈티컬스, 인크. | 동결건조 의약품의 목표 잔류 수분 함량 |
| US20220040305A1 (en) * | 2020-08-07 | 2022-02-10 | Janssen Biotech, Inc. | Formulations for highly purified viral particles |
| KR20230092820A (ko) * | 2020-08-22 | 2023-06-26 | 페더럴 스테이트 버지터리 인스티튜션 “내셔널 리서치 센터 포 에피데미올로지 앤드 마이크로바이올로지 네임드 애프터 더 아너러리 아카데미시안 엔.에프. 감마레야” 오브 더 미니스트리 오브 헬스 오브 더 러시안 페더레이션 | Sars-cov-2에 대한 특이적 면역을 유도하기 위한 약제학적 제제 |
| WO2022067273A1 (en) * | 2020-09-24 | 2022-03-31 | Nant Holdings Ip, Llc | Vaccine compositions for mucosal immune response |
| CN116348134A (zh) * | 2020-10-23 | 2023-06-27 | 河谷控股Ip有限责任公司 | 用于黏膜免疫应答的疫苗组合物 |
| CA3198538A1 (en) * | 2020-11-16 | 2022-05-19 | Bakul Subodh BHATNAGAR | Enhanced formulation stabilization and improved lyophilization processes |
| CN116829134A (zh) * | 2020-11-16 | 2023-09-29 | 生物技术欧洲股份公司 | 包含rna的lnp组合物及其制备、储存和使用方法 |
| US20240033334A1 (en) * | 2020-12-04 | 2024-02-01 | Gritstone Bio, Inc. | Compositions and methods of use thereof |
| CN114903922B (zh) * | 2021-02-09 | 2024-04-26 | 武汉博沃生物科技有限公司 | 包含腺病毒的医药配制品及其保存方法 |
| CN119677546A (zh) | 2022-07-12 | 2025-03-21 | 吉利德科学公司 | Hiv免疫原性多肽和疫苗及其用途 |
| CN116350801A (zh) | 2022-11-22 | 2023-06-30 | 四川至善唯新生物科技有限公司 | 一种重组腺相关病毒载体的药物组合物及其用途 |
| TW202426017A (zh) * | 2022-11-24 | 2024-07-01 | 俄羅斯聯邦商拜奧卡德聯合股份公司 | 非包膜病毒的藥物組合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7732129B1 (en) * | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| US6689600B1 (en) * | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| ATE449105T1 (de) * | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| ES2349472T3 (es) * | 2004-08-12 | 2011-01-03 | Schering Corporation | Formulación estable de interferón pegilado. |
| BRPI0618893A2 (pt) * | 2005-11-22 | 2011-09-13 | Wyeth Corp | formulações de proteìna de fusão de imunoglobulina |
| CN1883707A (zh) * | 2006-05-19 | 2006-12-27 | 吉林大学 | 重组腺病毒的冻干制剂及其制备方法 |
| HUE033656T2 (en) * | 2010-03-31 | 2017-12-28 | Stabilitech Ltd | Binders for stabilizing virus particles |
| EA201390812A1 (ru) * | 2010-12-02 | 2013-11-29 | Онколитикс Байотек Инк. | Лиофилизированные вирусные составы |
| HUE027839T2 (en) * | 2012-03-12 | 2016-11-28 | Crucell Holland Bv | Recombinant adenoviruses with altered terminals |
| US8932607B2 (en) * | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| WO2015040234A1 (en) * | 2013-09-23 | 2015-03-26 | Crucell Holland B.V. | Adenovirus formulations |
| GB201701239D0 (en) * | 2017-01-25 | 2017-03-08 | Glaxosmithkline Biologicals Sa | Novel formulation |
-
2015
- 2015-07-23 GB GBGB1513010.7A patent/GB201513010D0/en not_active Ceased
-
2016
- 2016-07-20 BR BR112018001260A patent/BR112018001260A2/pt not_active IP Right Cessation
- 2016-07-20 WO PCT/EP2016/067280 patent/WO2017013169A1/en not_active Ceased
- 2016-07-20 CA CA2992922A patent/CA2992922A1/en active Pending
- 2016-07-20 AR ARP160102193A patent/AR105401A1/es unknown
- 2016-07-20 MX MX2018001006A patent/MX391216B/es unknown
- 2016-07-20 CN CN201680054923.2A patent/CN108025081B/zh not_active Expired - Fee Related
- 2016-07-20 JP JP2018503207A patent/JP6797891B2/ja not_active Expired - Fee Related
- 2016-07-20 US US15/746,473 patent/US10722470B2/en active Active
- 2016-07-20 EP EP16751192.2A patent/EP3325016B1/en active Active
- 2016-07-20 BE BE2016/5605A patent/BE1023537B1/fr not_active IP Right Cessation
-
2021
- 2021-01-20 AR ARP210100121A patent/AR121079A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180214379A1 (en) | 2018-08-02 |
| MX391216B (es) | 2025-03-21 |
| GB201513010D0 (en) | 2015-09-09 |
| BE1023537A1 (fr) | 2017-04-26 |
| US10722470B2 (en) | 2020-07-28 |
| JP6797891B2 (ja) | 2020-12-09 |
| MX2018001006A (es) | 2018-06-06 |
| AR121079A2 (es) | 2022-04-13 |
| CN108025081B (zh) | 2021-11-02 |
| BR112018001260A2 (pt) | 2018-09-11 |
| JP2018521078A (ja) | 2018-08-02 |
| BE1023537B1 (fr) | 2017-04-26 |
| EP3325016C0 (en) | 2023-12-20 |
| WO2017013169A1 (en) | 2017-01-26 |
| EP3325016B1 (en) | 2023-12-20 |
| EP3325016A1 (en) | 2018-05-30 |
| CA2992922A1 (en) | 2017-01-26 |
| CN108025081A (zh) | 2018-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105401A1 (es) | Mezcla acuosa que comprende un vector adenoviral, composición liofilizada, procedimiento | |
| MX2015006617A (es) | Agente crioprotector, composiciones crioprotectoras y crioconservadas, usos de los mismos y metodos de crioconservacion. | |
| MX2015009552A (es) | Composiciones que incluyen agentes para conferir caracter hidrofobico y estabilizantes y metodos para elaborar y usar los mismos. | |
| MX2018002999A (es) | Composiciones de inoculante estables y metodos para producir las mismas. | |
| BR112017008499A2 (pt) | métodos e composições relacionadas com o uso de tensoativos de baixo valor de hlb na produção de nanoportadores sintéticos compreendendo um rapalog | |
| MX2016012168A (es) | Formulacion adyuvante no toxica que comprende una composicion de liposoma que contiene monofosforil-lipido a (mpla) y una saponina. | |
| EA201691911A1 (ru) | Быстродействующие композиции инсулина | |
| CL2015001376A1 (es) | Una escaladora vertical integral que comprende una estructura principalvertical integrada por dos perfiles rectangulares paraleos que soportan hasta 120 kg y estan unidos entre si por un puente porque la escaladora comprende una pieza en forma de "c" con caras triangulares, dispuesta en la cara frontal del perfil rectangular vertical. | |
| MX2017007178A (es) | Formulaciones liquidas estables de virus de vacuna. | |
| PE20161498A1 (es) | Composicion reactiva basada en bicarbonato de sodio y procedimiento para su produccion | |
| MX2017003205A (es) | Composiciones antimicrobianas y sus metodos de uso. | |
| BR112017026666A2 (pt) | armazenagem de longo prazo e conservação de plaquetas | |
| MX366276B (es) | Concepto de empalme de audio. | |
| ECSP20007842A (es) | Composiciones y métodos para formulaciones de alfavirus vivos atenuados | |
| WO2017062879A3 (en) | Dosing regimens | |
| MX377022B (es) | Composiciones de lágrimas artificiales. | |
| EP3539640A4 (en) | OXYGEN ABSORBING AGENT | |
| MX2018014278A (es) | Microparticulas que comprenden un compuesto que contiene azufre. | |
| CL2020000069A1 (es) | Mejora de las características del suelo con compuestos lactobionatos. | |
| AR086672A1 (es) | Formulaciones de furina recombinante | |
| CL2017001039A1 (es) | Composiciones anti-transpirantes anhidras | |
| BR112016028585A2 (pt) | composições herbicidas sólidas contendo um agente de proteção | |
| MX2017006914A (es) | Barras de limpieza con taurina. | |
| BR112016028662B8 (pt) | Composições herbicidas sólidas na forma de grânulos contendo um agente de proteção, e seu método de preparação | |
| UY37282A (es) | Composiciones protectoras de aminopiralida en especies de brassica con clopiralida y métodos para su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |